Table 1.
Steps for the diagnosis of atypical Hemolytic Uremic Syndrome (aHUS) in the study cohort.
Table 2.
Demographic and outcome characteristics of the patients treated with eculizumab after the kidney transplantation in the therapeutic use (group 1) prophylactic use (group 2).
Table 3.
Hematological parameters and kidney function of the patients on therapeutic use of eculizumab after the transplantation at time points: Immediately before infusion, 48 hours after, 6 months and at the end of follow up.
Fig 1.
Individual outcome of the hematological and kidney parameters of the patients on therapeutic use (group 1) of eculizumab after the kidney transplantation at time points: Immediately before infusion, 48 hours after, 6 months and at the end of follow up.
A: creatinine; B: estimated kidney function (eGFR); C: haptoglobin; D: platelets; E: LDH (lactate dehydrogenase); F: hemoglobin.